Medical Tech Stock Aethlon Medical (Nasdaq: $AEMD) Reports Fiscal Year 2026 Results as Australian Oncology Study Advances to Final Dosing Cohort

 

Medical Tech Stock Aethlon Medical (Nasdaq: $AEMD) Reports Fiscal Year 2026 Results as Australian Oncology Study Advances to Final Dosing Cohort

 

 

 

 

(Investorideas.com Newswire) Investorideas.com, a trusted investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment.

 

Industry commentary:

SentimenTrader: The firm notes that healthcare has quietly demonstrated strong defensive qualities, outperforming the S&P 500 on 85% of the days the broader market posted losses of 1% or more over the past year. This resilience underscores the sector’s potential as a reliable performer during market downturns. ubs.com

 

Aethlon Medical, Inc. (Nasdaq: AEMD) Aethlon Medical, Inc. today reported financial results for its fiscal year ended March 31, 2026, and provided an update on recent developments.

 

Summary - Australian oncology study advances into Cohort 3 as enrollment continues

 

Entered the third and final dosing cohort of the Australian oncology study, expanded the Hemopurifier intellectual property portfolio, and maintained a focus on managing operating expenses.

 

 

Conference Call Today at 4:30 p.m. ET

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/06101-aemd-fiscal-year-2026-results.asp

 

Key Highlights

 

·         Advanced the Australian oncology study through completion of the first two cohorts and entered the third and final dosing cohort, representing a key clinical milestone toward generating data to inform future development and dosing strategy.

 

·         Recently treated the first participant in Cohort 3 at Royal North Shore Hospital in Australia. The participant completed three Hemopurifier treatments over a one-week period, marking continued enrollment momentum and execution of the study's final treatment arm.

 

·         Advanced preclinical research evaluating Hemopurifier applications in additional disease areas, including rheumatoid arthritis and chronic kidney disease, supporting the expansion of the platform's potential addressable market beyond oncology and infectious disease.

 

 

·         Continued to strengthen the intellectual property portfolio supporting the Hemopurifier platform, including the issuance of patents in the United States and Europe covering potential applications for long COVID and other coronavirus-related conditions, extending patent protection into the 2040s and enhancing long-term platform value.

         

"Fiscal 2026 was a year of meaningful execution for Aethlon as we advanced our Australian oncology study through the first two cohorts and recently initiated Cohort 3. Advancement into the final cohort represents an important clinical milestone as we work toward generating data that may help define the optimal treatment regimen and guide future development decisions. We also strengthened the Hemopurifier platform through expansion of our intellectual property portfolio and advancement of preclinical research supporting potential applications beyond oncology. Combined with our continued focus on managing operating expenses, these achievements position us to pursue multiple value-creating opportunities across our clinical and research programs." said James Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical.

 

Clinical Update

Clinical Progress in Cancer Trial

 

Enrollment and treatment of participants in Cohort 2 of the Australian oncology trial have been completed. An independent Data Safety Monitoring Board reviewed the data, identified no safety concerns based on its review of available data, and recommended advancing to the third and final cohort. Screening is actively underway at the three investigative sites for this final cohort where 3-6 participants will be treated with 3 Hemopurifier sessions during a 1-week period. The first participant in Cohort 3 of the study has been enrolled and received three Hemopurifier treatments without any device deficiencies or immediate complications and is now in the follow-up period. Successful enrollment and treatment of the first participant in Cohort 3 maintains the study's clinical momentum and moves the Company closer to completing enrollment and generating data from all planned dosing regimens.

 

Serial Extracellular Vesicle and T cell measurements on participants in cohort 2 have been measured by the central lab at the University of Sydney. Formal statistical analyses comparing the effects of the three different Hemopurifier dosing regimens on these parameters will be performed by a CRO at the completion of the trial. This nine-to-18 patient study is designed to evaluate the safety and feasibility of the Hemopurifier treatments and determine the appropriate dosing in participants with solid tumors whose disease is stable or progressing while on a treatment that includes the anti-PD-1 agents, Keytruda® or Opdivo®.

 

Other Recent Developments

During fiscal 2026, we strengthened our intellectual property portfolio through the issuance of patents in both the United States and Europe covering potential applications of the Hemopurifier for coronavirus-related conditions, including long COVID and other post-infection complications. These patents extend protection for certain applications of the Hemopurifier into the 2040s and further strengthen the Company's intellectual property position surrounding the Hemopurifier.

 

In addition, we advanced our preclinical extracellular vesicle (EV) research activities, including studies evaluating removal of EVs in plasma samples from patients with rheumatoid arthritis and chronic kidney disease. These efforts support the Company's ongoing evaluation of the Hemopurifier's potential applications across multiple disease categories and may create future opportunities to expand the platform into large markets characterized by significant unmet medical need.

 

Separately, we continued our evaluation of Hemopurifier compatibility with a simplified blood treatment system being developed by Stavro Medical. Initial testing assessing flow rates and transfer of fluid through the Hemopurifier has been completed, and future studies evaluating removal of surrogate markers for extracellular vesicles by the Hemopurifier using the system are under consideration. We believe this approach could expand potential treatment settings for the Hemopurifier in the future and may improve the scalability and accessibility of treatment if successfully developed and validated.

 

Subsequent to fiscal year-end, an interview published in IEEE Spectrum featuring Aethlon's Chief Medical Officer and a physician involved in the treatment of an Ebola virus disease patient with the Hemopurifier during the 2014 outbreak highlighted the Company's experience with Ebola treatment efforts. In connection with renewed public health interest surrounding recent Ebola outbreaks, we also confirmed the continued availability of our FDA-authorized expanded access (compassionate use) protocol and shared the protocol as well as past in vitro and in vivo data with organizations involved in global and U.S. emerging pathogen preparedness efforts, including the World Health Organization's R&D Blueprint expert panel and the National Emerging Special Pathogen Training and Education Center.

 

Financial Results for the Fiscal Year Ended March 31, 2026

As of March 31, 2026, the Company had approximately $5.0 million in cash and cash equivalents, providing resources to support ongoing clinical and research activities.

 

Subsequent to fiscal year-end, the Company strengthened its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program.

 

Consolidated operating expenses declined 21.9% year-over-year to approximately $7.3 million, reflecting continued expense discipline and operational efficiency while advancing the Company's clinical and research priorities compared to $9.3 million for the fiscal year ended March 31, 2025. The decrease was primarily due to $1.1 million reduction in payroll and related expenses, a $500,000 reduction in general and administrative expenses and a $400,000 reduction in professional fees.

 

Consistent with the reduction in operating expenses, the operating loss for the fiscal year decreased to approximately $7.3 million for fiscal 2026 from $9.3 million in the prior fiscal year.

 

Other income was approximately $142,000 for the fiscal year ended March 31, 2026, primarily reflecting interest income earned on cash balances, compared to other expense of approximately $4 million in the prior fiscal year. The prior-year amount included approximately $4.7 million of non-cash financing-related charges.

 

Net loss attributable to our common stockholders was $7.2 million for the fiscal year ended March 31, 2026, compared to net loss of $13.4 million for the fiscal year ended March 31, 2025.

 

The consolidated balance sheets for March 31, 2026, and March 31, 2025, and the consolidated statements of operations for the fiscal years ended March 31, 2026, and 2025, are included at the end of this release.

 

Conference Call

Management will host a conference call today, Wednesday, June 10, 2026, at 4:30 p.m. ET to review the Company’s financial results and recent corporate developments. Following management’s formal remarks, there will be a question-and-answer session.

 

Interested parties can register for the conference call by navigating to  https://dpregister.com/sreg/10209612/1042263e8ec.  Please note that registered participants will receive their dial-in number upon registration.

 

Interested parties without internet access or unable to pre-register may dial in by calling:

 

PARTICIPANT DIAL IN (TOLL FREE): 1-844-836-8741

PARTICIPANT INTERNATIONAL DIAL IN: 1-412-317-5442

 

All callers should ask for the Aethlon Medical, Inc. conference call.

 

A replay of the call will be available approximately one hour after the end of the call through July 10, 2026. The replay can be accessed via Aethlon Medical’s website or by dialing 1-855-669-9658 (USA or Canada) or 1-412-317-0088 (international) or Canada toll free at 1-855-669-9658. The replay conference ID number is 7883435.

 

About the Hemopurifier®

The Aethlon Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived extracellular vesicles (EVs) from circulation. It is used extracorporeally with a blood pump and combines plasma separation, size exclusion, and affinity binding using a plant lectin resin that targets mannose-rich surfaces found on EVs and viruses. EVs released by solid tumors are believed to play a role in metastasis and the resistance to immunotherapies and chemotherapy. Removal of enveloped viruses and extracellular vesicles has been demonstrated in both in vitro studies and human subjects.

 

The Hemopurifier holds a U.S. Food and Drug Administration Breakthrough Device Designation for:

 

The treatment of individuals with advanced or metastatic cancer unresponsive to or intolerant of standard-of-care therapy; and the treatment of life-threatening viruses not addressed with approved therapies.

 

Full news and financials from AEMD

https://www.aethlonmedical.com/news-media/press-releases/detail/523/aethlon-medical-announces-fiscal-year-end-march-31-2026

 

Aethlon Medical (Nasdaq:AEMD) is a featured biotech stock on Investorideas.com

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

 

Get News Alerts on Aethlon Medical

Disclaimer/Disclosure: Aethlon Medical, Inc. is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

Research biotech stocks at Investorideas.com

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

 

 

 

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

 

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

 

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411

 

VisionWave Holdings (Nasdaq: $VWAV) Strengthens Position in AI-Based Defense Tech with Foresight Autonomous Acquisition; @VWAVInc

 

VisionWave Holdings (Nasdaq: $VWAV) Strengthens Position in AI-Based Defense Tech with Foresight Autonomous Acquisition; @VWAVInc

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV).

VisionWave Holdings, Inc (Nasdaq: VWAV), an advanced sensing technology company developing AI-driven, RF-based sensing and computational acceleration technologies for defense and commercial uses, today announced it has executed a definitive agreement with respect to the proposed strategic acquisition of controlling interest in Foresight Autonomous Holdings Ltd. (Nasdaq: FRSX). According to the Agreement, VisionWave will acquire up to 52% of Foresight’s outstanding shares in exchange for $17.5 million in VisionWave’s shares of common stock.

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/06091-visionwave-foresight-autonomous-acquisition.asp

The global sensor market size was valued at USD 241.06 billion in 2025 and is projected to grow from USD 258.47 billion in 2026 to USD 527.94 billion by 2034

The definitive agreement with Foresight will add important sensing technology to the Company’s STRATUM™ SENSE suite of sensing technologies, and follows the Company’s latest acquisition of the xClibre™ AI video intelligence IP portfolio, which was independently valued at approximately $60 million by BDO Consulting Group as of the acquisition date for financial reporting purposes. This valuation is based on certain assumptions and methodologies and does not necessarily represent current fair market value, future realizable value, or the amount at which the assets could be sold or monetized.

Modern defense and security environments demand sensing systems that can detect, identify, classify, and act - quickly and across multiple domains simultaneously. With the definitive agreement now in place, VisionWave is positioned to deliver the architecture with enhanced performance.

RF Sensing Layer

VisionWave’s own RF-based AI detection, wide-area, all-weather threat awareness at range

Optical and Thermal Computer Vision Sensing Layer

Foresight’s camera-based stereo and thermal perception, proven across automotive and defense programs

AI Video Intelligence

xClibre™ behavioral analytics- turning existing camera infrastructure into continuously-learning AI agents

The convergence of these three layers, RF detection, multi-spectral computer vision, and AI-driven video analytics, produces a perception capability beyond what any single-modality company can deliver. RF tells you something is there. Foresight’s optics tell you where it is and how it’s moving. xClibre tells you what it’s doing and whether it is a threat.

Today, perception technology across defense and security is fragmented. RF specialists don’t build video AI. Video AI vendors don’t build RF. Autonomous systems integrators buy from multiple vendors and stitch together incompatible stacks. With this definitive agreement executed, it is VisionWave’s goal to eliminate this fragmentation and deliver a unified, superior multi-modal perception platform, for use with any UxV (Unmanned X Vehicle).

For demonstration purposes see - Foresight 3D Perception Stereoscopic Visible Light vs. Thermal video:

Merging visible light cameras and thermal LWIR cameras.

Rendering of segmentation and detection

TRANSACTION SUMMARY

Under the agreement, VisionWave will acquire a controlling interest of up to 52% stake in Foresight through a two-stage share exchange: 46% of Foresight’s issued and outstanding ordinary shares upon Stage 1 Closing (expected within 45-60 days), with the right to an additional 6% upon achievement of a defined commercial milestone - the commencement of a binding pilot project integrating the Perception Platform in the commercial, defense, or security sector. In exchange, VisionWave will issue newly issued shares of its common stock with an aggregate value of approximately $17.5 million (calculated based on the five-day volume-weighted average price preceding each closing), plus up to $3 million in management equity grants. VisionWave will also gain significant board representation, with the right to designate two directors to Foresight’s Board upon Stage 1 Closing and one additional director upon Stage 2 Closing.  The transaction remains subject to customary closing conditions, including regulatory approvals, Nasdaq listing requirements (if applicable), and any required shareholder approvals.

Both companies will continue to operate as independent, publicly traded entities. The transaction positions VisionWave to establish its core operating platform for RF-focused perception systems and related defense, security, and autonomous technology initiatives by integrating Foresight’s high-resolution visible light/infra-red and neuromorphic event-based sensor suite.

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the execution and closing of the transaction with Foresight Autonomous Holdings Ltd., the expected benefits of the acquisition, integration of technologies into the STRATUM™ SENSE suite, achievement of commercial milestones, anticipated board representation, operational synergies, and the Company’s strategic initiatives in defense and security sensing. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," and similar expressions, or by statements that events or trends "may," "will," or "could" occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to, risks related to the completion of the transaction on the proposed terms or at all (including failure to obtain required approvals or satisfy closing conditions), integration challenges, dilution from equity issuance, market volatility affecting VWAV share price used for consideration, regulatory scrutiny of the acquisition, technological development risks, competition in the defense sector, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company's SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact: investors@vwav.inc

 

Watch recent VWAV video

https://www.youtube.com/shorts/wr4R7VSy7VM

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire 

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 

 

 

AI Stock VisionWave Holdings (Nasdaq: $VWAV) Unveils Breakthrough DeepWave RF Sensing Tech for Oil, Gas & Critical Minerals Exploration; @VWAVInc

 

AI Stock VisionWave Holdings (Nasdaq: $VWAV) Unveils Breakthrough DeepWave RF Sensing Tech for Oil, Gas & Critical Minerals Exploration; @VWAVInc

 

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV), a technology company focused on advanced sensing, artificial intelligence, imaging, and autonomous technologies.

VisionWave Holdings, Inc (Nasdaq: VWAV) announced today that it plans to unveil DeepWave RF™, its proprietary near-bit subsurface sensing initiative, at AOW Energy 2026, scheduled to be held September 1-3, 2026, in Accra, Ghana.

 

DeepWave RF™ is a development-stage technology initiative designed to evaluate the use of advanced radio-frequency (“RF”) sensing, artificial intelligence (“AI”), software-defined radio architectures, and real-time computational modeling to assist in the detection, characterization, and interpretation of subsurface geological structures during drilling operations.

 

The Company continues to evaluate DeepWave RF™ but believes it may represent a novel approach to the significant challenges in the exploration industry: obtaining actionable information regarding geological conditions ahead of the drill bit before drilling into a formation.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/06021-visionwave-vwav-deepwave-rf-sensing-oil-gas.asp

 

VisionWave also announced that it has filed U.S. Provisional Patent Application No. 64/032,626, entitled “Near-Bit Subsurface RF Sensing Systems,” with the United States Patent and Trademark Office on April 8, 2026. The provisional patent application relates to various aspects of the DeepWave RF™ initiative, including near-bit RF sensing architectures, signal processing methodologies, AI-assisted interpretation systems, and subsurface imaging techniques.  The filing of a provisional patent application does not guarantee the issuance of a patent or any particular scope of claims.

 

DeepWave RF™ is being developed with the goal of evaluating whether adaptive RF sensing techniques can provide drilling operators and exploration teams with enhanced awareness of subsurface conditions ahead of the drilling assembly. The initiative seeks to bridge the gap between traditional deep resistivity tools and high-resolution radar technologies by pursuing a practical balance between sensing range and spatial resolution.  

 

The technology architecture under evaluation incorporates advanced sensing hardware, software-defined radio platforms, edge computing, physics-informed neural networks, machine learning models, and real-time inversion techniques designed to transform RF measurements into actionable geological information.  

 

Although there is no assurance of commercialization, potential future applications under evaluation include:

* Oil and natural gas exploration;

* Geothermal resource development;

* Critical mineral and rare-earth element exploration;

* Metallic mineral discovery;

* Groundwater resource identification;

* Geological mapping and subsurface characterization; and

* Geosteering and drilling optimization.  

\

VisionWave Chief Technology Officer Dr. Danny Rittman, inventor of the DeepWave RF™ technology, is expected to present the initiative during AOW Energy 2026 before an audience that includes national oil companies, ministries of energy, regulators, exploration companies, investors, and technical professionals from across Africa and the international energy sector.

“AOW Energy provides an exceptional platform to introduce DeepWave RF™ to industry leaders, regulators, national oil companies, and potential strategic partners,” said Douglas Davis, Chief Executive Officer and Executive Chairman of VisionWave. “We believe the filing of U.S. Provisional Patent Application No. 64/032,626 marks an important milestone in the development of this initiative and reflects VisionWave’s commitment to advancing innovative sensing technologies that may create new opportunities within the global exploration industry.”

 

Dr. Danny Rittman added:

“For decades, the drilling industry has pursued the goal of obtaining meaningful visibility ahead of the drill bit before entering a formation. We believe DeepWave RF™ represents our effort to evaluate whether advances in radio-frequency sensing, artificial intelligence, software-defined radio technology, and real-time computational modeling can contribute to achieving that objective. While the initiative remains in the research and development stage, we believe the concepts merit discussion and evaluation by the global exploration community.”

 

VisionWave’s participation at AOW Energy 2026 follows ongoing discussions regarding the application of advanced sensing technologies to frontier exploration opportunities and reflects the Company’s broader strategy of expanding the use of its sensing and AI capabilities into additional commercial markets.

 

The Company expects to participate in conference activities, engage with government and industry stakeholders, exhibit its technology initiatives, and discuss potential future applications of DeepWave RF™ within the exploration and resource development sectors.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc .

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding DeepWave RF™ development, patent filings, conference participation, technology evaluation, potential applications, operational deployment across platforms, proof-of-concept timelines, intellectual property realization, strategic initiatives, and the Company’s future business plans. These statements are based on current expectations, assumptions, and beliefs and are subject to numerous risks and uncertainties, many of which are beyond the Company’s control.

Forward-looking statements are generally identified by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "project," "forecast," "predict," and similar expressions, or by statements that events or trends "may," "will," or "could" occur.

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including but not limited to: risks associated with the research, development, testing, and technical feasibility of early-stage technologies such as DeepWave RF™; uncertainties regarding the issuance, scope, or enforceability of patents from provisional applications; challenges in integrating acquired intellectual property; delays or failure to achieve proof-of-concept validation or commercial adoption; availability of funding; regulatory approvals and defense contracting requirements; market acceptance of new sensing and AI platforms; competition in autonomous defense and resource exploration sectors; general economic conditions; and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company's SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

Contact: investors@vwav.inc

Watch recent VWAV video

https://www.youtube.com/shorts/wr4R7VSy7VM

 

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411